<DOC>
	<DOCNO>NCT01636778</DOCNO>
	<brief_summary>The purpose study assess ability SB-497115-GR raise platelet count thrombocytopenic patient hepatitis C virus ( HCV ) infection ( platelet count &lt; 80,000 /μL , suggestive compensate cirrhosis ) level desirable initiate antiviral therapy ass ability SB-497115-GR maintain platelet count level sufficient minimise dose reduction pegylated interferon ( Peg-IFN ) ribavirin ( RBV ) therapy expectation lower rate Peg-IFN dose reduction omission translate high rate sustain viral response .</brief_summary>
	<brief_title>Japanese Phase II Study SB-497115-GR Hepatitis C Virus Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Subject able understand comply protocol requirement instruction likely complete study plan , well provide write consent . A subject age ≥20 &lt; 75 year time inform consent . A subject apply one following : Female subject nonchildbearing potential [ i.e. , physiologically incapable become pregnant , : hysterectomy , bilateral oophorectomy ( ovariectomy ) , bilateral tubal ligation , postmenopausal great one year ] . Female subject childbearing potential , negative urine serum pregnancy test screening within 24hour period prior first dose SB497115GR , completely abstain intercourse agree use two follow acceptable method contraception 14 day exposure SB497115GR , throughout clinical trial , 24 week completion premature discontinuation study . Intrauterine device intrauterine system meet effectiveness criterion state product label . Male partner sterilization prior female subject 's entry study , male sole partner subject . Doublebarrier contraception ( condom spermicidal jelly , diaphragm spermicide ) . Male subject childbearing potential partner completely abstain intercourse agree use condom diaphragm spermicide . Subjects diagnose hepatitis C compensate liver cirrhosis ( ChildPugh class A ) without hepatic encephalopathy , ascites . If clear cirrhosis , treatment give care potential progressing liver failure . Subjects , opinion investigator , appropriate candidate PegIFN RBV combination therapy 48 week . HCV positive TaqMan test screening . Subject fulfil organ function . Items Values Platelet &lt; 80,000 /μL Haemoglobin ≥12.0 g/dL* Absolute neutrophil count ( ANC ) ≥1500 /μL* Creatinine clearance &gt; 50 mL/minute Total bilirubin &lt; 2.0 mg/dL Albumin &gt; 3.0 g/dL Prothrombin time &gt; 60 % *If investigator consider value sufficient give PegIFN/RBV , subject enrol upon consult Medical Monitor . Subject relapse respond 48 week PegIFN/RBV therapy give sufficient dose previously . Subject history IFN ( include PegIFN ) therapy PegIFN/RBV therapy , could treat optimal PegIFN/RBV therapy due reason thrombocytopenia . Subject receive IFN therapy ( include PegIFN ) , antiviral therapy ( exclude oseltamivir phosphate , etc . ) , immunomodulatory treatment , radiotherapy phlebotomy within 3 month ( 90 day ) prior first dose SB497115GR . Treatment investigational drug within 30 day prior first dose SB497115GR 5 halflives investigational drug ( whichever longer ) . Subject decompensated liver disease . Chronic liver disease chronic hepatitis C ( e.g. , autoimmune hepatitis , alcoholinduced hepatitis , druginduced hepatitis , etc. ) . Subject idiopathic thrombocytopenic purpura active autoimmune disease . Subject malignancy diagnose and/or treat within past 5 year . Subjects require endoscopic treatment varix document history clinically significant bleed oesophageal gastric varix . Any disease condition associate active bleeding require anticoagulation heparin warfarin . Subject serious cardiac , cerebrovascular , chronic pulmonary disease interstitial lung disease , document history disease . Preexisting cardiac disease ( congestive heart failure New York Heart Association Grade III/IV ) , arrhythmias know involve risk thromboembolic event ( e.g . atrial fibrillation ) , subject QTcF &gt; 450 msec bundle brunch block , QTcF &gt; 480 msec . Subject depression , psychiatric disorder require treatment suicidal ideation suicide attempt history , history . Subject uncontrolled hypertension ( ≥160 mmHg systolic ≥100 mmHg diastolic ) . Subject diabetes mellitus control treatment . Thyroid dysfunction adequately control . Subjects haemoglobinopathy . History current condition seizure disorder . Subject positive Human Immunodeficiency Virus ( HIV ) antibody Hepatitis B Virus ( HBV ) antigen . Subject arterial venous thrombosis history evidence portal vein thrombosis abdominal imaging ( e.g. , computerized tomography magnetic resonance imaging ) within 3 month . History alcohol/drug abuse dependence . History platelet clump prevents reliable measurement platelet count . Subjects plan cataract surgery . History major organ transplantation . Known hypersensitivity SB497115GR ingredient , IFN ( include PegIFN ) , nucleoside analogues biological agent ( i.e. , vaccine ) . Pregnant nursing woman male subject pregnant partner .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Thrombocytopenia</keyword>
	<keyword>Hepatitis C , chronic</keyword>
</DOC>